A Study of Tirbanibulin on the Wellbeing of Participants With Actinic Keratoses
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 342
- Registration Number
- NCT05741294
- Locations
- 🇮🇹
Almirall Investigational Site 3, Rimini, Italy
🇪🇸Almirall Investigational Site 1, Valencia, Spain
🇪🇸Almirall Investigational Site 2, Zaragoza, Spain
UV Sensor in Patients With Actinic Keratosis
- Conditions
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 10
- Registration Number
- NCT05481073
- Locations
- 🇪🇸
Dermatology Unit (Hospital Clinic), Barcelona, Spain
A Study of Tirbanibulin Ointment and Diclofenac Sodium Gel for the Treatment of Adult Participants With Actinic Keratosis on the Face or Scalp
- Conditions
- Interventions
- First Posted Date
- 2022-05-24
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 450
- Registration Number
- NCT05387525
- Locations
- 🇵🇱
Almirall Investigational Site 402, Wrocław, Poland
🇵🇱Almirall Investigational Site 27, Kraków, Poland
🇫🇷Almirall Investigation Site 104, Nice, France
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
- First Posted Date
- 2022-03-15
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 105
- Registration Number
- NCT05279131
- Locations
- 🇺🇸
Almirall Investigational Site 1, College Station, Texas, United States
🇺🇸Almirall Investigation Site 7, Hot Springs, Arkansas, United States
🇺🇸Almirall Investigation Site 3, Sweetwater, Florida, United States
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 300
- Registration Number
- NCT05260073
- Locations
- 🇺🇸
Almirall Investigational Site 1, Charleston, South Carolina, United States
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
- Conditions
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 331
- Registration Number
- NCT05149313
- Locations
- 🇫🇷
Alm Site 12, Reims, France
🇳🇱Alm Site 35, Utrecht, Netherlands
🇫🇷Alm Site 19, Lille, France
Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE Study
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 782
- Registration Number
- NCT04823247
- Locations
- 🇩🇪
Haut- und Laserzentrum Freising, Freising, Bavaria, Germany
Patient-reported Outcomes for Sarecycline Effectiveness and Safety (PROSES)
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 300
- Registration Number
- NCT04820673
- Locations
- 🇺🇸
Almirall Site#2, Boston, Massachusetts, United States
🇺🇸Almirall Site #1, Brooklyn, New York, United States
Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque Psoriasis
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2021-12-08
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 47
- Registration Number
- NCT04339595
- Locations
- 🇵🇱
Site 0002, Wroclaw, Poland
🇵🇱Site 0003, Łódź, Poland
🇵🇱Site 0001, Wroclaw, Poland
Study of Pidotimod in Children With Recurrent Respiratory Tract Infections (RRI)
- Conditions
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Almirall, S.A.
- Target Recruit Count
- 338
- Registration Number
- NCT04322669
- Locations
- 🇨🇳
Investigator Site 01 Children's Hospital Captial Institute of Pediatrics, Beijing, China
🇨🇳Investigator Site 16, Changchun, China
🇨🇳Investigator Site 03, Nanjing, China